What it tests
Whether the ANA AC-21 (reticular cytoplasmic) pattern represents true anti-mitochondrial antibodies (AMA), confirming the hypothesized pathway: POLE haploinsufficiency → elevated mutations in nuclear-encoded mitochondrial genes → mitochondrial protein dysfunction → membrane perturbation → AMA production.
Method
- AMA-specific ELISA: Anti-PDC-E2 (pyruvate dehydrogenase complex E2 subunit), anti-BCOADC-E2, anti-OGDC-E2 — the three canonical AMA targets
- Liver function panel: GGT, alkaline phosphatase — assess subclinical biliary dysfunction (PBC screening given liver FNH/hemangioma + potential AMA)
- Extended autoimmune panel: Anti-dsDNA, ENA panel, complement C3/C4, anti-smooth muscle antibodies — determine whether ANA positivity is isolated to AC-21 or indicates broader immune dysregulation
- Mitochondrial function assays (if available): Seahorse XF on patient-derived PBMCs for OCR/ECAR; MitoSOX for mitochondrial ROS
Expected outcomes
- AMA positive (anti-PDC-E2): Confirms mitochondrial immune targeting; connects POLE mutagenesis to organelle-level pathology. Generates testable prediction that autoantibody profiling should be part of systematic POLE carrier phenotyping.
- AMA negative, AC-21 pattern from other antigens: AC-21 represents a different autoimmune target; mitochondrial hypothesis weakened but not excluded
- Broad autoimmune positivity: Systemic immune dysregulation — may reflect POLE-driven neoantigen generation beyond tumor-specific antigens
- Elevated GGT/ALP: Subclinical PBC; clinically actionable finding
Priority justification
Tier-1: Simple blood tests (ELISA, standard autoimmune panels). No PPAP cohort has ever been systematically screened for AMA or organelle-targeting autoantibodies. A positive result would open an entirely new dimension of POLE carrier phenotyping and connects to mitochondrial biology.
Key references
- ICAP AC-21 pattern: reticular cytoplasmic, characteristically associated with AMA targeting inner mitochondrial membrane antigens
- AMA are the serological hallmark of primary biliary cholangitis (PBC)
What it tests
Whether the ANA AC-21 (reticular cytoplasmic) pattern represents true anti-mitochondrial antibodies (AMA), confirming the hypothesized pathway: POLE haploinsufficiency → elevated mutations in nuclear-encoded mitochondrial genes → mitochondrial protein dysfunction → membrane perturbation → AMA production.
Method
Expected outcomes
Priority justification
Tier-1: Simple blood tests (ELISA, standard autoimmune panels). No PPAP cohort has ever been systematically screened for AMA or organelle-targeting autoantibodies. A positive result would open an entirely new dimension of POLE carrier phenotyping and connects to mitochondrial biology.
Key references